The 2021 San Antonio Breast Cancer Symposium

Highlights of the latest research

Presenters at the 2021 San Antonio Breast Cancer Symposium (SABCS; December 7–10) reported the latest findings in breast cancer research. NEJM Journal Watch Oncology and Hematology Editor-in-Chief Dr. William Gradishar summarizes and provides perspective for some of the key studies. Abstracts can be viewed via the SABCS site or the links provided.

Novel Oral SERD Improves Outcomes in Metastatic Breast Cancer That Progressed on Endocrine Therapy

Elacestrant monotherapy reduces risk for death and disease progression by 30% compared with standard of care in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer that progressed on endocrine therapy, according to the industry-funded, phase 3 EMERALD trial (abstract GS2-02…

Author

William J. Gradishar, MD

Disclosures

Consultant/Advisory BoardLilly; AstraZeneca; Gilead

Grant/Research SupportBreast Cancer Research Foundation

Editorial BoardsClinical Breast Cancer; Oncology; Annals of Surgery; Breast Cancer Research and Treatment

Leadership Positions in Professional SocietiesNational Comprehensive Cancer Network (Chair, Breast Cancer Panel); American Board of Internal Medicine (Medical Oncology Board)